十一月 2025
- Home
- Genomic Health Inc
十一月 2025的Genomic Health Inc市场份额分析
Genomic Health was a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California. The company was acquired by and merged with Exact Sciences Corporation in 2019.
Genomic Health Inc(包含公司地区分支机构)
查看更多网站流量和参与度信息- genomichealth.com
Genomic Health Inc收入截至 十一月 2025为 200M - 500M
Genomic Health Inc主要域名产生的收入
3 年中Genomic Health Inc主要域名的收入
Genomic Health Inc主要域名的收入
Genomic Health Inc热门域名的总访问量
了解Genomic Health Inc市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Genomic Health Inc热门域名的平均访问时长
分析Genomic Health Inc参与度指标。
过去 3 个月的平均访问时长
子公司明细
Genomic Health Inc热门域名的平均页面浏览量
了解Genomic Health Inc如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Genomic Health Inc 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻MDxHealth partnered with Genomichealth on Aug 2nd '22.MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an asset purchase agreement with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation (“Exact Sciences”), to acquire the Oncotype DX® GPS (Genomic Prostate Score®) test from Exact Sciences along with most of its team of urology sales and marketing professionals.
八月 1, 2022阅读更多
新闻Genomichealth launched Oncotype DX AR-V7 nucleus detect test on Feb 1st '18.March 2018 – Oncotype DX AR-V7 nucleus detect test, a predictive and prognostics biomarker was launched by Genomic Health Inc.
十月 28, 2021阅读更多
新闻Genomichealth hired F. Murray as System Chief of the Division of Genomic Medicine and Clinical Director of the Institute on Sep 26th '23.Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
九月 25, 2023阅读更多
查看 Genomic Health Inc 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。